MGTX
MeiraGTxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Bull case assumes positive clinical readouts and at least one partnering/licensing deal within three months that materially de-risks programs and accelerates milestones, prompting re-rating versus peers.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.5.
What can break
Clinical trial failure or safety signal
Momentum
93
Value
48
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.33 · Bull $9.38 · Bear $3.52
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $28.38
Why
Momentum93 · Δ7d -0.5
Value48 · Δ7d 0.0
Sentiment2 · Δ7d +1.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
+7.7
Value
48
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.1
Sentiment
2
34% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
-2.9
Why this grade
Composite grade D. Momentum 93.1 / Value 48.5 / Sentiment 2.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.13B
Beta
1.38
Shares Out
92.61M
P/E (TTM) · Derived
-8.6
P/S (TTM)
22.17
P/FCF (TTM) · Derived
260.90
Rev YoY
-84.8%
EPS YoY
+12.6%
Gross Margin
+79.8%
Op Margin
-597.9%
Net Debt
$22.76M
Current Ratio
0.55
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology